Savara (NASDAQ:SVRA) Stock Price Up 6.6% – Time to Buy?

Savara Inc. (NASDAQ:SVRA) shot up 6.6% during mid-day trading on Wednesday . The company traded as high as $5.26 and last traded at $5.2550. 278,516 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 1,514,531 shares. The stock had previously closed at $4.93.

Analyst Upgrades and Downgrades

SVRA has been the topic of several analyst reports. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. William Blair set a $10.00 target price on Savara in a research report on Monday, March 16th. Finally, Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Stock Up 3.1%

The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -9.08 and a beta of 0.26. The stock’s 50 day moving average is $5.30 and its 200 day moving average is $5.59.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Prudential Financial Inc. acquired a new position in shares of Savara during the second quarter valued at approximately $30,000. BNP Paribas Financial Markets grew its position in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in Savara in the second quarter worth approximately $33,000. Russell Investments Group Ltd. grew its position in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Savara in the third quarter worth approximately $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.